Therefore, in order to be able to choose when to start EGFR–TKIs especially osimertinib, in this study, we evaluated OS in patients with long‐term follow‐up and investigated the impact of variables on the prognosis in EGFR‐positive NSCLC patients with PR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.